Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11755664 | 0.92 | MEN1 (0.70) | MEN1KMT2ATAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL8324517 | 0.92 | TAS1R3 (0.65) | MEN1KMT2ATAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL6356934 | 0.87 | HDAC3 (0.74) | MEN1KMT2AHDAC3HDAC2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9639590 | 0.86 | HDAC3 (0.72) | MEN1KMT2AHDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL12989186 | 0.84 | SMN1; SMN2 (0.66) | HDAC3HDAC2SMN1; SMN2HTT | |
| SCHEMBL9360969 | 0.83 | HDAC3 (0.58) | HDAC3HDAC2SMN1; SMN2SMPD1POLB | |
| SCHEMBL11752307 | 0.83 | MEN1 (0.60) | MEN1KMT2ATAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL931440 | 0.83 | POLB (0.73) | HDAC3HDAC2SMPD1POLBRAB9A | |
| SCHEMBL11240645 | 0.82 | POLB (0.76) | MEN1KMT2AHDAC3HDAC2SMPD1 | |
| SCHEMBL3880413 | 0.82 | POLB (0.76) | MEN1KMT2AHDAC3HDAC2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | MEN1 903/4885KMT2A 2755/4885TAS1R3 127/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | MEN1 903/4885KMT2A 2755/4885TAS1R3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.